​

Royalty Pharma (RPRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RPRX Stock Forecast

Royalty Pharma (RPRX) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $43.33, with a high of $51.00 and a low of $28.00. This represents a 33.53% increase from the last price of $32.45.

$25 $31 $37 $43 $49 $55 High: $51 Avg: $43.33 Low: $28 Last Closed Price: $32.45

RPRX Stock Rating

Royalty Pharma stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

RPRX Price Target Upside V Benchmarks

TypeNameUpside
StockRoyalty Pharma33.53%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$45.00
Last Closing Price$32.45$32.45$32.45
Upside/Downside--38.67%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25351--9
Mar, 25351--9
Feb, 25351--9
Jan, 25451--10
Dec, 24451--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 04, 2024Chris ShibutaniGoldman Sachs$51.00$29.1674.90%57.16%
Jul 11, 2024Terence FlynnMorgan Stanley$51.00$25.7398.21%57.16%
Jun 07, 2024Chris ShibutaniGoldman Sachs$50.00$27.0984.57%54.08%
Jun 03, 2024Ashwani VermaUBS$28.00$27.352.38%-13.71%
Dec 06, 2022Morgan Stanley$51.00$42.8718.96%57.16%
Jun 13, 2022Ashwani VermaUBS$47.00$38.4622.20%44.84%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 28, 2025CitigroupBuyBuyhold
Sep 04, 2024Goldman SachsBuyBuyhold
Aug 13, 2024Goldman SachsBuyBuyhold
Jul 11, 2024Morgan StanleyOverweightOverweighthold
Jun 12, 2024Johnson RiceOverweightOverweighthold
Jun 07, 2024Goldman SachsBuyBuyhold
Jun 03, 2024UBSBuyNeutraldowngrade
May 23, 2024NeedhamBuyBuyhold
May 17, 2024Cowen & Co.BuyBuyhold
Dec 06, 2022Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 $9 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.32$1.15$0.10$3.41$1.92----
Avg Forecast$2.46$2.86$3.64$4.24$4.05$4.40$4.98$7.16$8.00
High Forecast$2.69$3.14$3.83$4.25$4.08$5.02$6.14$7.42$8.29
Low Forecast$2.22$2.59$3.30$4.23$4.01$4.13$4.24$6.56$7.33
Surprise %-46.34%-59.79%-97.25%-19.58%-52.59%----

Revenue Forecast

$2B $2B $3B $4B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.12B$2.29B$2.24B$2.35B$2.26B----
Avg Forecast$1.80B$2.16B$2.79B$2.99B$2.70B$2.98B$3.30B$3.94B$4.39B
High Forecast$1.93B$2.31B$2.91B$3.01B$2.71B$3.00B$3.41B$4.05B$4.52B
Low Forecast$1.67B$2.00B$2.59B$2.97B$2.52B$2.95B$3.19B$3.69B$4.11B
Surprise %17.78%6.21%-19.85%-21.14%-16.05%----

Net Income Forecast

$0 $1B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$495.20M$478.75M$42.83M$1.13B$859.00M----
Avg Forecast$1.48B$645.49M$475.79M$1.13B$2.44B$2.76B$3.13B$4.22B$4.82B
High Forecast$1.62B$774.59M$570.94M$1.36B$2.46B$3.03B$3.70B$4.47B$5.00B
Low Forecast$1.34B$516.39M$380.63M$907.87M$2.42B$2.49B$2.55B$3.96B$4.42B
Surprise %-66.61%-25.83%-91.00%--64.77%----

RPRX Forecast FAQ

Is Royalty Pharma stock a buy?

Royalty Pharma stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Royalty Pharma is a favorable investment for most analysts.

What is Royalty Pharma's price target?

Royalty Pharma's price target, set by 10 Wall Street analysts, averages $43.33 over the next 12 months. The price target range spans from $28 at the low end to $51 at the high end, suggesting a potential 33.53% change from the previous closing price of $32.45.

How does Royalty Pharma stock forecast compare to its benchmarks?

Royalty Pharma's stock forecast shows a 33.53% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Royalty Pharma over the past three months?

  • April 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Royalty Pharma’s EPS forecast?

Royalty Pharma's average annual EPS forecast for its fiscal year ending in December 2025 is $4.4, marking a 129.17% increase from the reported $1.92 in 2024. Estimates for the following years are $4.98 in 2026, $7.16 in 2027, and $8 in 2028.

What is Royalty Pharma’s revenue forecast?

Royalty Pharma's average annual revenue forecast for its fiscal year ending in December 2025 is $2.98B, reflecting a 31.50% increase from the reported $2.26B in 2024. The forecast for 2026 is $3.3B, followed by $3.94B for 2027, and $4.39B for 2028.

What is Royalty Pharma’s net income forecast?

Royalty Pharma's net income forecast for the fiscal year ending in December 2025 stands at $2.76B, representing an 221.14% increase from the reported $859M in 2024. Projections indicate $3.13B in 2026, $4.22B in 2027, and $4.82B in 2028.